Ductal carcinoma in situ (DCIS) accounts for one out of every five new breast cancer cases. While nearly all DCIS is curable, there are many treatment options to consider.
Through Breast Cancer Care at Penn Medicine, we have the expertise to detect and diagnose small tumors in the earliest stages of DCIS. Our specialized breast cancer team then works with you to create an individualized treatment plan.
What is ductal carcinoma in situ (DCIS)?
Ductal carcinoma in situ is a type of breast cancer (abnormal cells) found in the milk ducts of the breast. Unlike other types of breast cancer, DCIS is noninvasive, meaning it has not spread to surrounding tissue or other parts of the body like metastatic breast cancer does. DCIS is the earliest stage of breast cancer and is considered stage 0.
DCIS is typically detected through breast cancer screening such as a mammogram. While you may notice a lump or slight nipple discharge, DCIS rarely presents with the usual symptoms of breast cancer. DCIS may become invasive if left untreated, so early detection is critical.
Ductal carcinoma in situ symptoms and diagnosis
Generally, there are no signs or symptoms of ductal carcinoma in situ. It is usually not something that a patient or physician can feel. Some people have a lump or slight discharge from the nipple, but most cases of DCIS are found on a mammogram. If DCIS is suspected on a mammogram, a breast biopsy may be ordered to confirm a breast cancer diagnosis.
Staging ductal carcinoma in situ
Your Penn Medicine physician will use breast cancer staging to help determine the type of treatment you will receive. Ductal carcinoma in situ is considered Stage 0 on the TNM staging system. It is the earliest form of breast cancer, in which the cancer cells are still within a duct and have not invaded deeper into the surrounding fatty breast tissue.
What is the prognosis for a DCIS diagnosis?
Because ductal carcinoma in situ is a non-invasive, early-stage form of breast cancer the outlook for most people diagnosed with DCIS is generally positive after receiving the appropriate treatment. However, some studies have shown that a small population of people with certain risk factors, including age and ethnicity, may be at increased risk for a more advanced or aggressive type of breast cancer. Your Penn Medicine health care provider will be able to speak with you in more detail about your specific prognosis.
Treating DCIS at Penn Medicine
We treat DCIS before it becomes invasive breast cancer. Your care team works with you to create a treatment plan that is both effective and personalized to your diagnosis and lifestyle. Penn Medicine offers many different breast cancer treatment options available through our breast cancer care program.
Can you prevent DCIS?
While there is no true way to prevent ductal carcinoma in situ, annual mammograms can help detect DCIS early. Early detection of DCIS and other breast cancer types can lead to better outcomes with less invasive treatment.
While preventing DCIS specifically is unlikely, there are certain risk factors for breast cancer to be aware of. People with a strong family history or those that are worried about developing breast cancer should maintain a healthy lifestyle and avoid the risks that are within their control, such as excessive alcohol consumption and not being physically active.
Why choose Penn Medicine for DCIS treatment?
We understand the importance of accurately diagnosing and treating DCIS. At Penn Medicine, you can expect:
- Precise diagnosis: Our specialized breast cancer pathologists gather detailed information about your type of cancer. This information helps us personalize your treatment with a comprehensive breast cancer diagnosis.
- Timely treatment: We provide a quick response to early-stage breast cancer. Our certified breast cancer nurse navigators may coordinate your appointments so that your treatment begins as soon as possible.
- Comprehensive care: Our oncologists work together to address every aspect of your care. In addition to innovative treatments, we offer extensive breast cancer support services to manage any side effects.
- Attention to breast cancer recurrence: After a breast cancer diagnosis, your risk of new and recurrent cancer increases. Our 2-PREVENT Breast Cancer Translational Center of Excellence addresses cancer concerns that arise after your treatment ends.
- Care close to home: You’ll find expert breast cancer care at all Penn Medicine breast cancer care locations. Our breast cancer specialists and staff collaborate seamlessly across the network to get you the treatment you need, no matter where you live.
- Access to the latest research: Penn Medicine’s Basser Center for BRCA is dedicated to delivering the latest research, therapies, and education on BRCA-related cancers.
Rated “exceptional” by The National Cancer Institute
Penn Medicine’s Abramson Cancer Center is a world leader in cancer research, patient care, and education. Our status as a national leader in cancer care is reflected in our continuous designation as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 7 such centers in the United States. The ACC is also a member of the National Comprehensive Cancer Network, one of a select few cancer centers in the U.S., that are working to promote equitable access to high-quality, advanced cancer care.